Key Highlights
- HeartBeam appoints Lance Myers, PhD, as Chief AI Scientist to lead AI applications in cardiac care technology.
- Company’s AI-driven approach aims to transform heart diagnostics with data-rich signals and 12-lead ECG synthesis.
- HeartBeam’s technology is FDA under review and supported by 13 US and 4 international patents.
- Myers brings expertise from Verily Life Sciences, specializing in AI for cardiac monitoring and health informatics.
Source: Business Wire
Notable Quotes
- “His insights and expertise will have an immediate impact as we strive to transform cardiac care by harnessing the power of AI with our data-rich technology.” — Branislav Vajdic, PhD, CEO and Founder at HeartBeam
- “By leveraging longitudinal trends and increasing user data, we can uncover new insights, pushing the boundaries of AI in cardiac care and bringing transformative advancements to patients.” — Lance Myers, PhD, Chief AI Scientist at HeartBeam
SoHC's Take
HeartBeam’s strategic appointment of Lance Myers, PhD, underscores the growing importance of AI in the evolution of cardiac care technology. Myers’ proven track record in digital health data analytics and body-worn biosensors, combined with HeartBeam’s innovative 12-lead ECG system, signals a new era in remote heart diagnostics. With FDA submissions under review and cutting-edge AI developments in progress, HeartBeam is well-positioned to revolutionize cardiac health management by offering a more personalized, data-driven approach to patient care.
